Does ATORVASTATIN Cause Immune-mediated hepatitis? 9 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Immune-mediated hepatitis have been filed in association with ATORVASTATIN (Atorvastatin calcium). This represents 0.0% of all adverse event reports for ATORVASTATIN.
9
Reports of Immune-mediated hepatitis with ATORVASTATIN
0.0%
of all ATORVASTATIN reports
0
Deaths
6
Hospitalizations
How Dangerous Is Immune-mediated hepatitis From ATORVASTATIN?
Of the 9 reports, 6 (66.7%) required hospitalization, and 1 (11.1%) were considered life-threatening.
Is Immune-mediated hepatitis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ATORVASTATIN. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does ATORVASTATIN Cause?
Type 2 diabetes mellitus (7,556)
Myalgia (7,155)
Drug hypersensitivity (3,929)
Drug ineffective (3,865)
Fatigue (3,439)
Arthralgia (3,338)
Rhabdomyolysis (3,286)
Dyspnoea (3,137)
Nausea (2,888)
Asthenia (2,791)
What Other Drugs Cause Immune-mediated hepatitis?
NIVOLUMAB (640)
PEMBROLIZUMAB (549)
IPILIMUMAB (443)
CARBOPLATIN (213)
PACLITAXEL (167)
ATEZOLIZUMAB (142)
BEVACIZUMAB (108)
DURVALUMAB (90)
LENVATINIB (86)
PEMETREXED (86)
Which ATORVASTATIN Alternatives Have Lower Immune-mediated hepatitis Risk?
ATORVASTATIN vs ATORVASTATIN\EZETIMIBE
ATORVASTATIN vs ATOSIBAN
ATORVASTATIN vs ATOVAQUONE
ATORVASTATIN vs ATOVAQUONE\PROGUANIL
ATORVASTATIN vs ATRACURIUM